Added to YB: 2025-07-11
Pitch date: 2025-05-23
ELEV [bullish]
Elevation Oncology, Inc.
+15.62%
current return
Author Info
No bio for this author
Company Info
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.
Market Cap
$22.4M
Pitch Price
$0.32
Price Target
0.46 (+26%)
Dividend
N/A
EV/EBITDA
0.59
P/E
-0.47
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Elevation Oncology, Inc. - $ELEV
ELEV: Near-term liquidation of negative EV biotech. $33M cash by 6/30, no debt after repaying $32M loan, no active trials. After failed seribantumab & EO-3021, ceased R&D, cut 70% workforce. Upside 45%, NAV $0.46/sh ($27.5M after burn/fees). Catalyst: formal liquidation announcement.
Read full article (1 min)